Join to view full profile
520 Country Club PkwyEugene, OR 97401
Phone+1 541-683-5001
Fax+1 541-683-1422
Dr. Sharman is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 2005 - 2008
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2001 - 2004
University of California, Davis, School of MedicineClass of 2001
Certifications & Licensure
CA State Medical License 2004 - Present
OR State Medical License 2008 - 2027
MA State Medical License 2003 - 2006
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification iKnowMed Generation 2, McKesson, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification iKnowMed EHR, McKesson, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification iKnowMed EHR, McKesson, 2012, 2014-2017
Clinical Trials
- A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
- Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14
- MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10
Publications & Presentations
PubMed
- Loncastuximab and Rituximab in Elderly Unfit/Frail Patients With Previously Untreated Diffuse Large B-Cell Lymphoma.Ranjit Nair, Abhijeet Kumar, Andrew E Chapman, Moshe Yair Levy, Jeff P Sharman
Blood Advances. 2026-10-15 - Corrigendum to "Epcoritamab Monotherapy as Outpatient Treatment for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Interim Results From EPCORE NHL-6"...David Andorsky, Adelba Torres Lopez, Rakhee Vaidya, Fernando Vargas Madueno, Sami Ibrahimi
Clinical Lymphoma, Myeloma & Leukemia. 2026-09-16 - 1 citationsPatient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plu...Paolo Ghia, Davide Rossi, Emmanuelle Ferrant, Fátima de la Cruz Vicente, Dai Maruyama
Journal of Geriatric Oncology. 2026-07-01
Journal Articles
- An Open‐Label Phase 2 Trial of Entospletinib in Indolent Non‐Hodgkin Lymphoma and Mantle Cell LymphomaJeff P Sharman, David J Andorsky, Christopher A Yasenchak, Kathryn S Kolibaba, British Journal of Haematology
- IdelalisibFurhman, New England journal
Abstracts/Posters
- Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Final Results from the Phase II GIBB St...Jeff P. Sharman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analys...Jeff P. Sharman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Evolution in Practice Patterns and Differences Among Experts and Community Healthcare Providers in the Treatment of Patients with Chronic Lymphocytic LeukemiaJeff P. Sharman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Final Results from the Multicenter, Open-Label, Phase II GIBB Study of Obinutuzumab+Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Indolent Lymphomas: The Marathon Has a New Course61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Press Mentions
Ghosts in the Blood: The Extraordinary History of Chronic Lymphocytic LeukemiaAugust 18th, 2026- Bispecifics Rise, ADCs Fall? Top News in Diffuse Large B-cell Lymphoma at ASH 2025January 8th, 2026
- Elderly or Unfit Patients with DLBCL May Benefit From Subcutaneous MosunetuzumabDecember 15th, 2025
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: